This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blumer, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blumer, J. L.

PEDIATRICS Vol. 104 No. 3 Supplement September 1999, pp. 582

Introduction

Jeffrey L. Blumer, PhD, MD

The first 20% of the full text of this article appears below.

Our ability to provide safe and effective drug therapy for infants and children is often hampered by a lack of dosing information derived from careful, well-controlled trials and the limited database available concerning drug safety in this patient population. This problem was first articulated 30 years ago by Dr Harry Shirkey from the Children's Hospital in Birmingham, Alabama. He termed infants and children the "therapeutic orphans."

For the last 3 decades a small group of dedicated and highly motivated pediatricians and . . . [Full Text of this Article]